{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T15:00:37Z","timestamp":1773154837160,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.msard.2019.08.016","type":"journal-article","created":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T17:13:01Z","timestamp":1565889181000},"page":"101374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["The long-term effects of disease modifying therapies on disability in people living with multiple sclerosis: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6545-946X","authenticated-orcid":false,"given":"Suzi B.","family":"Claflin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2807-0070","authenticated-orcid":false,"given":"Bruce V.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.msard.2019.08.016_bib0001","first-page":"1732","article-title":"Immunomodulatory therapies delay disease progression in multiple sclerosis","volume":"22","author":"Bergamaschi","year":"2016","journal-title":"MSJ"},{"key":"10.1016\/j.msard.2019.08.016_bib0002","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.3389\/fneur.2018.01150","article-title":"The effect of disease modifying therapies on disability progression in multiple sclerosis: a systematic overview of meta-analyses","volume":"9","author":"Claflin","year":"2019","journal-title":"Front Neurol."},{"key":"10.1016\/j.msard.2019.08.016_bib0003","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1191\/1352458504ms990oa","article-title":"the European IFN\u03b2-1a dose-comparison study investigators. interferon \u03b2-1a in relapsing multiple sclerosis: four-year extension of the European IFN\u03b2-1a dose-comparison study","volume":"10","author":"Clanet","year":"2004","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.msard.2019.08.016_bib0004","first-page":"433","article-title":"Influence of treatments in multiple sclerosis disability: a cohort study","volume":"21","author":"Cocco","year":"2015","journal-title":"MSJ"},{"issue":"14","key":"10.1016\/j.msard.2019.08.016_bib0005","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1212\/WNL.0b013e31824e8ee7","article-title":"Alemtuzumab more effective than interferon \u03b2-1a at 5-year follow-up of CAMMS223 clinical trial","volume":"78","author":"Coles","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2019.08.016_bib0006","doi-asserted-by":"crossref","first-page":"k4674","DOI":"10.1136\/bmj.k4674","article-title":"Disease-modifying therapies for multiple sclerosis","volume":"363","author":"De Angelis","year":"2018","journal-title":"BMJ"},{"issue":"Suppl 1","key":"10.1016\/j.msard.2019.08.016_bib0007","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.clineuro.2013.09.024","article-title":"Interferon-beta and disability progression in relapsing-remitting multiple sclerosis","volume":"115","author":"Drulovic","year":"2013","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"19","key":"10.1016\/j.msard.2019.08.016_bib0008","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1212\/WNL.0000000000001608","article-title":"The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail?","volume":"84","author":"Hartung","year":"2015","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.msard.2019.08.016_bib0009","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1177\/1352458509105229","article-title":"Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiples sclerosis","volume":"15","author":"Havrdova","year":"2009","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2019.08.016_bib0010","first-page":"1277","article-title":"University of british columbia MS\/MRI analysis group. interferon beta-1a in the treatment of multiple sclerosis","volume":"45","year":"1995","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2019.08.016_bib0011","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1474-4422(17)30007-8","article-title":"Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study","volume":"16","author":"Kalincik","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2019.08.016_bib0012","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.msard.2017.09.012","article-title":"Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: efficacy and safety results up to 7 years","volume":"18","author":"Lublin","year":"2017","journal-title":"Mult. Scler. Rel. Dis."},{"key":"10.1016\/j.msard.2019.08.016_bib0013","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.msard.2017.11.006","article-title":"A 8-year retrospective cohort study comparing interferon-\u03b2 formulations for relapsing-remitting multiple sclerosis","volume":"19","author":"Moccia","year":"2018","journal-title":"Mult. Scler. Rel. Dis."},{"issue":"5","key":"10.1016\/j.msard.2019.08.016_bib0014","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1474-4422(15)00018-6","article-title":"Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK multiple sclerosis risk sharing scheme at 6 years: a clinical cohort study with natural history comparator","volume":"14","author":"Palace","year":"2015","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.msard.2019.08.016_bib0015","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1600-0404.2005.00565.x","article-title":"Effects of interferon beta-1a and -1b over time: 6-year results of an observational head-to-head study","volume":"113","author":"Patti","year":"2006","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.msard.2019.08.016_bib0016","article-title":"Natalizumab for relapsing remitting multiple sclerosis (Review)","volume":"10","author":"Pucci","year":"2011","journal-title":"Cochrane Database Systematic Rev."},{"key":"10.1016\/j.msard.2019.08.016_bib0017","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00415-005-0748-5","article-title":"Interferon beta in relapsing-remitting multiple sclerosis: an eight years experience in a specialist multiple sclerosis centre","volume":"252","author":"R\u00edo","year":"2005","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2019.08.016_bib0018","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jama.2012.7625","article-title":"Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis","volume":"308","author":"Shirani","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.msard.2019.08.016_bib0019","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.msard.2016.01.007","article-title":"Long-term impact of interferon or Glatiramer acetate in multiple sclerosis: A systematic review and meta-analysis","volume":"6","author":"Signori","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2019.08.016_bib0020","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/nrneurol.2014.237","article-title":"Can we measure long-term treatment effects in multiple sclerosis?","volume":"11","author":"Sormani","year":"2015","journal-title":"Nature Rev. Neurol."},{"key":"10.1016\/j.msard.2019.08.016_bib0021","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.msard.2019.08.016_bib0022","unstructured":"Sterne J.A.C., Higgins J.P.T., Elbers R.G., Reeves bc and the development group for ROBINS-I. risk of bias in non-randomized studies of interventions (ROBINS-I): detailed guidance, updated 12 October2016b. Available fromhttp:\/\/www.riskofbias.info [accessed 2018]."},{"issue":"6","key":"10.1016\/j.msard.2019.08.016_bib0023","first-page":"765","article-title":"Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs","volume":"19","author":"Tedeholm","year":"2013","journal-title":"MSJ"},{"key":"10.1016\/j.msard.2019.08.016_bib0024","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1007\/s10072-005-0511-9","article-title":"The IFN\u03b2 treatment of multiple sclerosis (MS) in clinical practice: the experience at the MS center of Bari, Italy","volume":"26","author":"Trojano","year":"2005","journal-title":"Neurol. Sci."},{"issue":"4","key":"10.1016\/j.msard.2019.08.016_bib0025","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/ana.21102","article-title":"New natural history of interferon-\u03b2-treated relapsing multiple sclerosis","volume":"61","author":"Trojano","year":"2007","journal-title":"Ann. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2019.08.016_bib0026","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/ene.12698","article-title":"Beta-interferon exposure and onset of secondary progressive multiple sclerosis","volume":"22","author":"Zhang","year":"2015","journal-title":"Eur. J. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819303517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819303517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:45:19Z","timestamp":1761900319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034819303517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":26,"alternative-id":["S2211034819303517"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2019.08.016","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The long-term effects of disease modifying therapies on disability in people living with multiple sclerosis: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2019.08.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101374"}}